Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice

Virology Journal

Volumn 5, Issue , 2008, Pages

  Israyelyan, Anna ^a   Chouljenko, Vladimir N ^a   Baghian, Abolghasem ^a   David, Andrew T ^a   Kearney, Michael T ^a   Kousoulas, Konstantin G ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NV 1020; ONCDSYN; ONCOLYTIC VIRUS; ONCSYN; GLYCOPROTEIN B, SIMPLEXVIRUS; UL53 PROTEIN, HUMAN HERPESVIRUS 1; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; METASTASIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; VERO CELL; VIRUS GENOME; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; ESCHERICHIA COLI; EXPERIMENTAL NEOPLASM; GENETIC RECOMBINATION; GENETICS; LUNG TUMOR; METABOLISM; METHODOLOGY; MUTATION;

ANIMALIA; BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 1; MURINAE; MUS; MUS MUSCULUS;

ANIMALS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; GENOME, VIRAL; HERPESVIRUS 1, HUMAN; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MUTATION; ONCOLYTIC VIROTHERAPY; RECOMBINATION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

EID: 46949094436     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-68     Document Type: Article

References (49)

1. Oncolytic viruses. EA Chiocca, Nat Rev Cancer 2002 2 938 950 10.1038/nrc948 12459732
2. Oncolytic virotherapy as a novel treatment platform for cancer. D Kirn, Ernst Schering Res Found Workshop 2003 89 105 12894453
3. Selectively replicating viral vectors. J Nemunaitis J Edelman, Cancer Gene Ther 2002 9 987 1000 10.1038/sj.cgt.7700547 12522438
4. Live viruses in cancer treatment. J Nemunaitis, Oncology (Williston Park) 2002 16 1483 1492 discussion 1495-1487 12469927
5. Herpes simplex virus-based vectors. R Lachmann, Int J Exp Pathol 2004 85 177 190 10.1111/j.0959-9673.2004.00383.x 15312123
6. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. X Fu M Nakamori L Tao R Amato X Zhang, Int J Oncol 2007 30 1561 1567 17487379
7. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. X Fu L Tao R Cai J Prigge X Zhang, Mol Ther 2006 13 882 890 10.1016/j.ymthe.2006.02.007 16569513
8. DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome. CA Meseda F Schmeisser R Pedersen A Woerner JP Weir, Virology 2004 318 420 428 10.1016/j.virol.2003.09.033 14972567
9. Incorporation of a lambda phage recombination system and EGFP detection to simplify mutagenesis of Herpes simplex virus bacterial artificial chromosomes. F Schmeisser JP Weir, BMC Biotechnol 2007 7 22 17501993 10.1186/1472-6750-7-22
10. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. DS Jeyaretna T Kuroda, Curr Opin Mol Ther 2007 9 447 466 17932809
11. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. DL Thomas NW Fraser, Mol Ther 2003 8 543 551 10.1016/S1525-0016(03)00236-3 14529826
12. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. T Todo SD Rabkin P Sundaresan A Wu KR Meehan HB Herscowitz RL Martuza, Hum Gene Ther 1999 10 2741 2755 10.1089/10430349950016483 10584921
13. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. CG Miller NW Fraser, Mol Ther 2003 7 741 747 10.1016/S1525-0016(03)00120-5 12788647
14. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. M Nakamori X Fu R Rousseau SY Chen X Zhang, Mol Ther 2004 9 658 665 10.1016/j.ymthe.2004.02. 019 15120326
15. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. H Li A Dutuor X Fu X Zhang, J Gene Med 2007 9 161 169 10.1002/jgm.1005 17266169
16. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. D Hoffmann W Bayer O Wildner, Hum Gene Ther 2007 18 435 450 10.1089/hum.2006.185 17518612
17. Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver. N Kemeny K Brown A Covey T Kim A Bhargava L Brody B Guilfoyle NP Haag M Karrasch B Glasschroeder, Hum Gene Ther 2006 17 1214 1224 10.1089/hum.2006.17.1214 17107303
18. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. CG Miller NW Fraser, Cancer Res 2000 60 5714 5722 11059765
19. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. PJ Cozzi PB Burke A Bhargav WD Heston B Huryk PT Scardino Y Fong, Prostate 2002 53 95 100 10.1002/pros.10138 12242723
20. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. PJ Cozzi S Malhotra P McAuliffe DA Kooby HJ Federoff B Huryk P Johnson PT Scardino WD Heston Y Fong, Faseb J 2001 15 1306 1308 11344122
21. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. A Gutermann E Mayer K Von Dehn-Rothfelser C Breidenstein M Weber M Muench D Gungor J Suehnel U Moebius M Lechmann, Hum Gene Ther 2006 17 1241 1253 10.1089/hum.2006.17.1241 17117895
22. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. PF McAuliffe WR Jarnagin P Johnson KA Delman H Federoff Y Fong, J Gastrointest Surg 2000 4 580 588 10.1016/S1091-255X(00)80106- 7 11307092
23. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. SJ Advani SM Chung SY Yan GY Gillespie JM Markert RJ Whitley B Roizman RR Weichselbaum, Cancer Res 1999 59 2055 2058 10232586
24. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. B Meignier R Longnecker B Roizman, J Infect Dis 1988 158 602 614 2842408
25. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). B Meignier B Martin RJ Whitley B Roizman, J Infect Dis 1990 162 313 321 2165104
26. Phase I trial of R7020: A live attenuated recombinant herpes simplex virus (HSV) candidate vaccine. M Cadoz JM Seigneurin MR Mallaret C Baccard P Morand, Program and Abstacts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy American Society of Microbiology, Washington, D.C 1992
27. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. J Chou ER Kern RJ Whitley B Roizman, Science 1990 250 1262 1266 10.1126/science.2173860 2173860
28. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. J Chou B Roizman, Proc Natl Acad Sci USA 1992 89 3266 3270 1314384 10.1073/pnas.89.8.3266
29. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. CM Kramm M Chase U Herrlinger A Jacobs PA Pechan NG Rainov M Sena-Esteves M Aghi FH Barnett EA Chiocca XO Breakefield, Hum Gene Ther 1997 8 2057 2068 10.1089/hum.1997.8. 17-2057 9414254
30. Nucleotide sequence specifying the glycoprotein gene, gB, of herpes simplex virus type 1. DJ Bzik BA Fox NA DeLuca S Person, Virology 1984 133 301 314 10.1016/0042-6822(84)90397-0 6324454
31. Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants. PE Pellett KG Kousoulas L Pereira B Roizman, J Virol 1985 53 243 253 2981343
32. Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion. DJ Bzik BA Fox NA DeLuca S Person, Virology 1984 137 185 190 10.1016/0042-6822(84) 90022-9 6089415
33. Fine structure physical map locations of alterations that affect cell fusion in herpes simplex virus type 1. VC Bond S Person, Virology 1984 132 368 376 10.1016/0042-6822(84)90042-4 6322419
34. Nucleotide sequence of a herpes simplex virus type 1 gene that causes cell fusion. C Debroy N Pederson S Person, Virology 1985 145 36 48 10.1016/0042-6822(85)90199-0 2990101
35. Functional and Physical Interactions of the Herpes Simplex Virus Type-1 (HSV-1) UL20 Membrane Protein with Glycoprotein K (gK). TP Foster VN Chouljenko KG Kousoulas, J Virol 2008
36. Herpes simplex virus type 1 glycoprotein K and the UL20 protein are interdependent for intracellular trafficking and trans-Golgi network localization. TP Foster JM Melancon TL Olivier KG Kousoulas, J Virol 2004 78 13262 13277 15542677 10.1128/JVI.78.23.13262-13277.2004
37. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. AH Israyelyan JM Melancon LG Lomax I Sehgal C Leuschner MT Kearney VN Chouljenko A Baghian KG Kousoulas, Hum Gene Ther 2007 18 457 473 10.1089/hum.2006.145 17536976
38. Cell fusion induced by herpes simplex virus is promoted and suppressed by different viral glycoproteins. R Manservigi PG Spear A Buchan, Proc Natl Acad Sci USA 1977 74 3913 3917 198812 10.1073/pnas.74.9.3913
39. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. BK Tischer J von Einem B Kaufer N Osterrieder, Biotechniques 2006 40 191 197 16526409
40. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. CJ Aslakson FR Miller, Cancer Res 1992 52 1399 1405 1540948
41. Genetics of natural resistance to herpes simplex virus type 1 latent infection of the peripheral nervous system in mice. LF Kastrukoff AS Lau ML Puterman, J Gen Virol 1986 67 Pt 4 613 621 10.1099/0022-1317-67-4-613 3007658
42. Genetics of natural resistance to herpesvirus infections in mice. C Lopez, Nature 1975 258 152 153 10.1038/258152a0 171586
43. Striking similarity of murine nectin-1alpha to human nectin-1alpha (HveC) in sequence and activity as a glycoprotein D receptor for alphaherpesvirus entry. D Shukla MC Dal Canto CL Rowe PG Spear, J Virol 2000 74 11773 11781 11090177 10.1128/JVI.74.24.11773-11781.2000
44. The requirements for herpes simplex virus type 1 cell-cell spread via nectin-1 parallel those for virus entry. DL Even AM Henley RJ Geraghty, Virus Res 2006 119 195 207 10.1016/j.virusres.2006.01.012 16823958
45. Some key problems for success of classical immunotherapy. AE Reif, Immunity to Cancer New York: Academic Press, Reif AE, Mitchell EMS, 1985 3 16
46. Models of progression spanning preneoplasia and metastasis: the human MCF10neoT.Tgn series and a panel of mouse mammary tumors subpopulations. FR Miller, Mammary tumor cell cycle, Differentiation, and Metastasis Boston: Kluwer Academic, Dickson MELRB, 1996 243 263
47. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. BA Pulaski S Ostrand-Rosenberg, Cancer Res 1998 58 1486 1493 9537252
48. Plasma membrane topology of syncytial domains of herpes simplex virus type 1 glycoprotein K (gK): the UL20 protein enables cell surface localization of gK but not gK-mediated cell-to-cell fusion. TP Foster X Alvarez KG Kousoulas, J Virol 2003 77 499 510 12477855 10.1128/JVI.77.1.499-510.2003
49. Glycoprotein K specified by herpes simplex virus type 1 is expressed on virions as a Golgi complex-dependent glycosylated species and functions in virion entry. TP Foster GV Rybachuk KG Kousoulas, J Virol 2001 75 12431 12438 11711633 10.1128/JVI.75.24.12431-12438.2001